Resolution Therapeutics

Resolution Therapeutics is a clinical stage biopharmaceutical company pioneering regenerative macrophage therapy in inflammatory and fibrotic diseases. Founded in 2020 from the cutting-edge research in macrophage and liver disease led by Prof. Stuart Forbes and Prof. John Campbell, Resolution raised over $130M from Syncona to become the leader in developing and manufacturing regenerative macrophage therapy. The company’s lead indication is ens-stage liver disease, the only chronic disease still on the rise in western countries, affecting millions of people worldwide. For patients with end-stage liver disease (cirrhosis) the only therapeutic option is liver transplantation, a complex surgical procedure limited by complications and a shortage of donors. The company’s lead product is an autologous engineered macrophage therapy designed to treat cirrhotic patients, currently in Phase I/II.

• Immunology/inflammation
• Stem Cells/Regenerative Medicine
• ATMP